BioSpace News Archive

Precision Optics Corporation, Inc., a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, announced that as of June 2, 2023, it entered into a new $750,000 term loan with Main Street Bank.

Vistagen today announced that PH80, one of the Company’s five investigational neuroactive nasal sprays, demonstrated statistically significant efficacy versus placebo in an exploratory Phase 2A study for the acute treatment of hot flashes (vasomotor symptoms) in women diagnosed with menopausal hot flashes.

Specialty cancer diagnostics company Precipio, Inc., announces that several operational improvement initiatives which commenced at the start of the year have begun to impact the cash burn and bottom line profitability.

The National Cancer Institute -designated Montefiore Einstein Cancer Center has received a five-year, $2.9 million grant from the NCI to train physicians and scientists to conduct clinical and translational oncology research, with a special emphasis on investigating and addressing health inequities in the Bronx.

Justera Health Ltd. (CSE: VTAL) (OTCQB: SCRSF) (formerly ScreenPro Security Inc.) (“Justera” or the “Company”) is pleased to announce the launch of its intravenous (IV) therapy lounge in Vancouver, now open to the public.

NanOlogy LLC, a clinical-stage oncology company, announces a presentation of clinical research involving its large surface area microparticle investigational drugs at DDW 2023 in May and publication at ASCO Annual Meeting in June.

DURECT Corporation announced that it has completed enrollment in its Phase 2b AHFIRM clinical trial investigating larsucosterol for the treatment of patients with severe alcohol-associated hepatitis, achieving its enrollment target of 300 patients.

AbTherx, Inc., a privately held biotech company with novel technologies that accelerate antibody discovery, announced the launch of its next-generation human antibody discovery platform.

FibroGen, Inc. announced topline data from the Phase 3 LELANTOS-1 placebo-controlled trial of pamrevlumab for the treatment of non-ambulatory patients with Duchenne Muscular Dystrophy on background corticosteroids.

Actinium Pharmaceuticals, Inc. announced that it will be added as a member of the small-cap Russell 2000® and all-cap Russell 3000® Indexes as part of the 2023 Russell indexes reconstitution, according to a preliminary list of additions posted May 19 and effective upon the U.S. market close on June 23, 2023.